Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 03 03:48PM ET
0.8603
Dollar change
-0.0295
Percentage change
-3.32
%
Index- P/E- EPS (ttm)-0.94 Insider Own10.93% Shs Outstand89.94M Perf Week-3.54%
Market Cap77.38M Forward P/E- EPS next Y-1.03 Insider Trans-0.01% Shs Float80.11M Perf Month-13.10%
Income-83.59M PEG- EPS next Q-0.26 Inst Own41.20% Short Float0.89% Perf Quarter-3.80%
Sales0.16M P/S483.60 EPS this Y-6.44% Inst Trans0.46% Short Ratio3.69 Perf Half Y-9.36%
Book/sh1.51 P/B0.57 EPS next Y-4.39% ROA-43.54% Short Interest0.71M Perf Year-14.82%
Cash/sh1.51 P/C0.57 EPS next 5Y- ROE-48.59% 52W Range0.75 - 1.30 Perf YTD-10.62%
Dividend Est.- P/FCF- EPS past 5Y8.31% ROI-61.28% 52W High-33.82% Beta1.02
Dividend TTM- Quick Ratio6.33 Sales past 5Y292.67% Gross Margin- 52W Low14.71% ATR (14)0.06
Dividend Ex-Date- Current Ratio6.33 EPS Y/Y TTM2.64% Oper. Margin-58380.50% RSI (14)41.71 Volatility6.41% 8.53%
Employees72 Debt/Eq0.01 Sales Y/Y TTM-85.98% Profit Margin-52574.84% Recom1.00 Target Price7.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q5.76% Payout- Rel Volume0.49 Prev Close0.89
Sales Surprise-91.67% EPS Surprise-10.17% Sales Q/Q136.36% EarningsNov 07 BMO Avg Volume192.42K Price0.86
SMA20-6.90% SMA50-5.32% SMA200-9.28% Trades Volume90,675 Change-3.32%
Date Action Analyst Rating Change Price Target Change
May-23-23Initiated Robert W. Baird Outperform $7
Sep-07-22Initiated CapitalOne Overweight $7
Apr-29-21Initiated Maxim Group Buy $20
Apr-23-21Resumed Cowen Outperform $10 → $18
Mar-31-21Initiated Wedbush Outperform $21
Mar-31-21Initiated Jefferies Buy $21
Feb-14-18Downgrade JP Morgan Neutral → Underweight
Feb-02-18Initiated H.C. Wainwright Buy $10
Aug-09-16Reiterated FBR Capital Mkt Perform $9 → $8
Feb-23-16Reiterated FBR Capital Mkt Perform $14 → $10
Nov-11-24 07:00AM
Nov-08-24 02:22AM
02:12AM
Nov-07-24 08:35AM
07:35AM
07:00AM Loading…
07:00AM
Nov-06-24 07:50AM
Nov-01-24 07:00AM
Oct-18-24 04:31PM
Sep-03-24 07:00AM
Aug-30-24 04:05PM
Aug-14-24 06:14AM
Aug-13-24 08:15AM
07:14AM
07:00AM
08:45AM Loading…
Aug-06-24 08:45AM
07:00AM
Jul-05-24 04:05PM
May-30-24 07:00AM
May-02-24 10:23AM
03:09AM
May-01-24 11:58PM
12:54PM
07:33AM
07:00AM
Apr-24-24 07:00AM
Apr-16-24 04:05PM
Mar-21-24 07:00AM
Mar-01-24 09:06AM
Feb-29-24 11:25PM
08:11AM Loading…
08:11AM
07:27AM
07:00AM
Feb-27-24 07:00AM
Feb-22-24 07:00AM
Dec-29-23 07:00AM
Dec-04-23 07:00AM
Nov-24-23 07:00AM
Nov-16-23 07:00AM
Nov-03-23 09:12AM
01:34AM
Nov-02-23 10:08AM
07:10AM
07:00AM
Oct-26-23 07:00AM
Oct-23-23 10:08AM
Sep-05-23 07:00AM
Aug-16-23 10:05AM
Aug-11-23 06:15AM
Aug-03-23 08:25AM
07:19AM
07:00AM
Jul-31-23 07:54AM
Jul-30-23 02:17PM
Jul-28-23 04:19PM
Jul-27-23 10:53AM
07:00AM
06:00AM
Jul-11-23 08:53PM
Jun-28-23 02:58PM
Jun-27-23 04:05PM
Jun-01-23 08:04PM
May-31-23 04:01PM
May-25-23 07:00AM
May-05-23 06:11AM
May-04-23 08:25AM
07:17AM
07:00AM
Apr-27-23 07:00AM
Apr-18-23 04:01PM
Mar-29-23 10:13AM
09:35AM
Mar-06-23 05:51AM
Mar-03-23 06:57PM
Mar-02-23 10:10PM
07:00AM
Feb-28-23 04:05PM
Feb-23-23 07:00AM
Feb-17-23 09:04AM
Feb-13-23 05:55PM
Feb-07-23 01:51PM
Feb-02-23 02:19PM
Jan-19-23 10:49AM
Jan-05-23 07:00AM
Dec-27-22 02:53PM
Dec-12-22 01:41PM
Dec-08-22 05:00PM
Nov-29-22 12:00PM
Nov-10-22 04:30PM
09:00AM
Nov-07-22 06:06AM
Nov-04-22 12:27PM
07:46AM
Nov-03-22 08:15AM
07:00AM
Nov-01-22 10:01AM
Oct-27-22 04:30PM
10:02AM
Oct-26-22 11:52AM
Sep-27-22 09:59PM
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Michael AndrioleOfficerAug 08 '24Proposed Sale0.871,5001,300Aug 09 01:26 PM
Andriole Michael T.PRESIDENT AND CEOAug 08 '24Sale0.831,2851,065462,453Aug 09 12:01 PM
Andriole Michael T.PRESIDENT AND CEOFeb 14 '24Sale1.041,7441,809447,021Feb 16 08:02 PM
LaSpaluto MichelleCHIEF FINANCIAL OFFICERFeb 14 '24Sale1.041,9402,023110,999Feb 16 08:01 PM
Jakeman DavidVP OF FINANCE AND ACCOUNTINGFeb 14 '24Sale1.042,6602,777141,232Feb 16 08:00 PM